The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in regenerative medicine Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers Average deal terms for regenerative medicine and stem cells
The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.
The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.
The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 1100 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format – by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Regenerative Medicine dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Regenerative Medicine dealmaking since 2014, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Regenerative Medicine deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Regenerative Medicine dealmaking with a brief summary followed by a comprehensive listing of Regenerative Medicine deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Regenerative Medicine partnering deals signed and announced since Jan 2014. The chapter is organized by specific Regenerative Medicine technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.
Key benefits Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits: In-depth understanding of Regenerative Medicine deal trends since 2014 Access to headline, upfront, milestone and royalty data Analysis of the structure of Regenerative Medicine agreements with numerous real life case studies Detailed access to actual Regenerative Medicine contracts entered into by leading biopharma companies Identify most active Regenerative Medicine dealmakers since 2014 Insight into terms included in a Regenerative Medicine partnering agreement, with real world examples Understand the key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 is intended to provide the reader with an in-depth understanding and access to Regenerative Medicine trends and structure of deals entered into by leading companies worldwide.
Regenerative Medicine Partnering Terms and Agreements includes: Trends in Regenerative Medicine dealmaking in the biopharma industry since 2014 Analysis of Regenerative Medicine deal structure Access to headline, upfront, milestone and royalty data Case studies of real-life Regenerative Medicine deals Access to Regenerative Medicine contract documents Leading Regenerative Medicine deals by value since 2014 Most active Regenerative Medicine dealmakers since 2014
In Global Regenerative Medicine Partnering Terms and Agreements 2014-2020, the available deals are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy target Technology type Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Regenerative Medicine Partnering terms and Agreements 2014-2020 report provides comprehensive access to available deals and contract documents for over 1100 Regenerative Medicine deals.
Analyzing actual contract agreements allows assessment of the following: • What are the precise rights granted or optioned? • What is actually granted by the agreement to the partner company? • What exclusivity is granted? • What is the payment structure for the deal? • How are sales and payments audited? • What is the deal term? • How are the key terms of the agreement defined? • How are IPRs handled and owned? • Who is responsible for commercialization? • Who is responsible for development, supply, and manufacture? • How is confidentiality and publication managed? • How are disputes to be resolved? • Under what conditions can the deal be terminated? • What happens when there is a change of ownership? • What sublicensing and subcontracting provisions have been agreed? • Which boilerplate clauses does the company insist upon? • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type? • Which jurisdiction does the company insist upon for agreement law?
Our reports have been used by over 10K customers, including:
The bioreactors market was valued at US$ 2,958.50 million in 2019 and is projected to reach US$ 5,169.01 million by 2027; it is expected to grow at a CAGR of 7.3% from 2020 to 2027. The increasing adoption of single-use bioreactors, and rapid growth of the pharmaceuticals and biotechnology industries are among the prime factors driving the...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Cell and Gene Therapy Market Report The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 2019–2025. The global cell and gene therapy market is one of the fastest-growing segments...
Osteonecrosis - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Osteonecrosis – Pipeline Review, H1 2020, provides an overview of the Osteonecrosis (Musculoskeletal Disorders) pipeline landscape. Osteonecrosis is bone death caused by poor blood...
Wounds - Pipeline Review, H1 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Wounds - Pipeline Review, H1 2020, provides an overview of the Wounds (Dermatology) pipeline landscape. Wound is a breakdown in the protective function of the skin (the loss of continuity...
Toll Like Receptor 4 - Pipeline Review, H1 2020 Summary According to the recently published report ’Toll Like Receptor 4 – Pipeline Review, H1 2020’; Toll Like Receptor 4 (hToll or CD284 or TLR4) pipeline Target constitutes close to 44 molecules. Out of which approximately 35 molecules are developed...
The Global Proteomics Partnering Terms and Agreements 2010 to 2020 report provides an understanding and access to the Proteomics partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Proteomics partnering deals Disclosed headlines, upfronts, milestones and royalties by...